Business Wire

Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo

Share

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura™) a topical JAK inhibitor, as a potential treatment for adolescents and adults (age ≥12 years) with vitiligo. The FDA grants Priority Review to medicines that may offer a major advance in treatment where none currently exists. The Prescription Drug User Fee Act (PDUFA) target action date is April 18, 2022.

“Vitiligo is a chronic autoimmune disease that can have a profound impact on people’s lives,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Currently, there are no FDA-approved drug therapies for repigmentation in people with vitiligo. The FDA’s acceptance of our sNDA for ruxolitinib cream brings us one step closer to offering patients with vitiligo an additional treatment option.”

The sNDA is supported by data from the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream in more than 600 people with non-segmental vitiligo, age 12 and older. Results from the Phase 3 program were recently presented at the 30th European Academy of Dermatology and Venereology (EADV) congress during a late-breaking research session. The data showed that at Week 24, 29.9% of patients applying ruxolitinib cream achieved ≥75% improvement from baseline in the facial Vitiligo Area Scoring Index (F-VASI75), the primary endpoint.

In September 2021, Opzelura™ (ruxolitinib) cream was approved by the FDA for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura™ in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.

About Vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of skin that results from the loss of pigment-producing cells known as melanocytes. Over-activity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of vitiligo. It affects approximately 1.5 million+ people in the U.S.1 and there are no U.S. Food and Drug Administration (FDA)-approved drug therapies for repigmentation in vitiligo. It can occur at any age, although many patients with vitiligo will experience initial symptoms before the age of 20.2

About TRuE-V

The TRuE-V clinical trial program includes two Phase 3 studies, TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573), evaluating the safety and efficacy of ruxolitinib cream in patients with vitiligo.

The studies each enrolled approximately 300 patients (age ≥12 years) who have been diagnosed with non-segmental vitiligo and have depigmented areas including at least 0.5% of the body surface area (BSA) on the face, ≥0.5 facial Vitiligo Area Scoring Index [F-VASI] score, at least 3% BSA on nonfacial areas, ≥3 total body Vitiligo Area Scoring Index [T-VASI] score and total BSA involvement (facial and nonfacial) of up to 10%. Participants were randomized into two arms: 1.5% ruxolitinib cream twice daily (BID) and vehicle control for the 24-week double-blind period. Patients who successfully completed baseline and Week 24 assessments, including those that received vehicle control during the double-blind phase, were offered treatment extension with 1.5% ruxolitinib cream BID for an additional 28 weeks.

The primary endpoint of both studies in the TRuE-V program is the proportion of patients achieving F-VASI75, defined as at least a 75% improvement from baseline in the F-VASI score at Week 24. Key secondary endpoints include: the proportion of patients achieving F-VASI50 (at least 50% improvement from baseline in the F-VASI), F-VASI90 (at least 90% improvement from baseline in the F-VASI) and T-VASI50 (at least 50% improvement from baseline in the T-VASI) at Week 24, the proportion of patients achieving a Vitiligo Noticeability Scale (VNS) score of 4 (a lot less noticeable) or 5 (no longer noticeable) at Week 24, and the percentage change from baseline in facial BSA (F-BSA) at Week 24. The studies also track the frequency, duration and severity of adverse events associated with the use of ruxolitinib cream.

For more information on the TRuE-V studies, please visit https://clinicaltrials.gov/ct2/show/NCT04052425 and https://clinicaltrials.gov/ct2/show/NCT04057573.

About Ruxolitinib Cream (Opzelura™)

Ruxolitinib cream (Opzelura) a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor approved for use in the United States for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended.

Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura. On October 28, 2021, Incyte announced the validation of the European Marketing Authorization Application (MAA) for ruxolitinib cream as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement.

Opzelura is a trademark of Incyte.

IMPORTANT SAFETY INFORMATION

OPZELURA cream is for use on the skin only. Do not use OPZELURA cream, in your eyes, mouth or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA cream contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death from all causes, including sudden cardiac death, has happened in people taking JAK inhibitors by mouth.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Some people have had lymphoma and other cancers while taking JAK inhibitors by mouth, especially if they are a current or past smoker. Some people have had skin cancers while taking OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA.

There is an increased risk of major cardiovascular events such as heart attack, stroke or cardiac death in people with cardiovascular risk factors and who are current or past smokers while using JAK inhibitors to treat inflammatory conditions.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.

Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.

Before starting OPZELURA, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have an infection that keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have or had TB, or have been in close contact with someone with TB
  • have had shingles (herpes zoster) or hepatitis B or C
  • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
  • think you have an infection or have symptoms of an infection such as:
  • fever, sweating, or chills
  • muscle aches
  • cough or shortness of breath
  • blood in your phlegm
  • weight loss
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than usual
  • feeling very tired
  • have ever had any type of cancer, or are a current or past smoker
  • have had blood clots in the veins of your legs or lungs in the past
  • have high cholesterol or triglycerides
  • have or have had low white or red blood cell counts
  • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463.
  • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose.

After starting OPZELURA:

  • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
  • Get emergency help right away if you have any symptoms of a heart attack or stroke while using OPZELURA, including:
    • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
    • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
    • pain or discomfort in your arms, back, neck, jaw, or stomach
    • shortness of breath with or without chest discomfort
    • breaking out in a cold sweat
    • nausea or vomiting
    • feeling lightheaded
    • weakness in one part or on one side of your body
    • slurred speech
  • Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OPZELURA, including: swelling, pain or tenderness in one or both legs, sudden, unexplained chest or upper back pain, or shortness of breath or difficulty breathing.
  • Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath or fever.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA include: pain or swelling in your nose or throat (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea).

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

About Incyte Dermatology

Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company’s research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.

Currently, Incyte is exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including vitiligo and hidradenitis suppurativa. To learn more, visit the Dermatology section of Incyte.com.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding whether and when ruxolitinib cream might be approved to treat patients with vitiligo, the potential for success of such treatment, Incyte’s TRuE-V clinical program and Incyte’s Dermatology program generally, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain, other third-party providers and development and discovery operations; determinations made by the FDA and other regulatory authorities; the efficacy or safety of the Company’s products; the acceptance of the Company’s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended September 30, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.


1 Bowcock, A; Fernandez-Vina, M. Targeting Skin: Vitiligo and Autoimmunity. J Invest Dermatol. https://www.sciencedirect.com/science/article/pii/S0022202X1535452X. Accessed November 22, 2021.
2 Rodrigues M. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017; 77:1-13.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Incyte:
Media
Jenifer Antonacci
+1 302 498 7036
jantonacci@incyte.com

Erica Cech
+1 302 274 4324
ecech@incyte.com

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SIGNA Sports United to Announce Fourth Quarter and Year-End 2021 Financial Results on January 26, 202218.1.2022 19:12:00 CET | Press release

SIGNA Sports United (“SSU” or the “Company”), the world’s leading sports e-commerce and technology platform, today announced that the company’s fourth quarter and year-end 2021 financial results will be released before the markets open on Wednesday, January 26, 2022. Management will host a call that day at 8:30 a.m. Eastern Time to discuss the results. Interested parties may access the conference call by dialing 1-855-979-6654 (in the United States) or +44 20 3936 2999 (outside of the United States), along with access code 690353. The conference call will be simulcast and archived on our website at https://investor.signa-sportsunited.com/. About SIGNA Sports United Inspiring performance. United by passion. SSU is a group of specialist sports webshops powered by our leading sports commerce and technology platform. Our specialist strategy allows us to uniquely spotlight the best of our 1000+ brand partners across the bike, tennis, outdoor and teamsports categories. Together we serve our

L&T Technology Services Wins USD45 Million EV Deal from U.S. Auto Tier 118.1.2022 17:46:00 CET | Press release

L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, announced that it has been awarded a deal worth USD45 million from a U.S. based automotive Tier 1 company, to be its strategic engineering partner and provide engineering services for its Electric Vehicle (EV) product portfolio. Under the terms of the 5-year agreement, LTTS will work with the customer to deliver solutions leveraging its e-mobility technology competence. Notably, this will be delivered from LTTS’ ER&D center in Krakow, Poland. LTTS plans to have over 300 engineers working from its Krakow, Poland center in the next 3 years, marking its expansion into Eastern Europe. Amit Chadha, CEO & Managing Director, L&T Technology Services said, “We have been investing in Electric, Autonomous and Connected Vehicle (EACV) as part of our 6 big bets and our engineers have developed several new scalable e-mobility solutions that can accelerate global automotive players’ EV d

Hillstone Networks Sets New Standard in Intelligent, Reliable and Automated Security Solutions With StoneOS 5.5R918.1.2022 17:00:00 CET | Press release

Hillstone Networks, a leading provider of infrastructure protection solutions, today introduced the latest iteration of its flagship StoneOS solution. “Organizations today demand a comprehensive, intelligent, high-performing and automated security solution that works. StoneOS delivers,” said Tim Liu, CTO & co-founder of Hillstone Networks. “This is a major upgrade resulting in unparalleled capabilities to help protect organizations, their critical assets and their workforces from the myriad of security threats they face every day.” 6 Key Updates to StoneOS 5.5R9 include: Machine learning technology leveraged to enhance intelligent detection and prevention – StoneOS leverages the latest ML-based data sets to help bolster DGA detection. The extended support of a cloud sandbox allows for improved unknown threat detection and enhanced intelligence sharing. Extended VPN capability delivers refined secure access for the remote workforce – The new additional VPN features support extended user

Mohammed bin Rashid honours 10 Winners of 2022 Zayed Sustainability Prize18.1.2022 16:02:00 CET | Press release

His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President, Prime Minister and Ruler of Dubai, presented awards to the 10 winners of the 2022 Zayed Sustainability Prize yesterday. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220118005713/en/ Mohammed bin Rashid honours 10 Winners of 2022 Zayed Sustainability Prize (Photo: AETOSWire) The Prize’s Awards Ceremony coincided with the start of the 2022 Abu Dhabi Sustainability Week (ADSW). The ceremony was also attended by H.H. Sheikh Maktoum bin Mohammed bin Rashid Al Maktoum, Deputy Ruler of Dubai, Deputy Prime Minister and Minister of Finance. His Highness Sheikh Mohammed bin Rashid Al Maktoum congratulated winners across the five categories reaffirming the Prize’s key role in realising the aspirations of participants to achieve sustainable development within their communities. This year, the Zayed Sustainability Prize, along with ADSW, joined forces with Expo 2020 Du

Pricefx Closes 2021 With Best Quarter in Company History18.1.2022 15:30:00 CET | Press release

Pricefx, the global leader in cloud pricing software, today announced it closed the best quarter in company history due to strong customer and partner traction in 2021. With 26 deals closed in Q4 2021 and 34 new enterprise customers added in 2021, the company ended the year with 45% year-over-year annual recurring revenue (ARR) growth. Key new customers include American Tire Distributors, Extreme Networks, KeHe Distributors and Tamko Building Products. Additionally, Pricefx recorded 95% customer retention and closed 23 customer expansion deals. In 2021, Pricefx increased revenue growth with SAP by 140% over 2020. The Advantage Pricefx partner program continued to drive significant return on investment in 2021 with at least one partner engaged on 70% of new customers signed through co-selling, influencing, and/or implementing the Pricefx solution. Several global system integrators, such as the KPMG German member firm, joined Pricefx’s ecosystem broadening the company’s reach and deepeni

Andersen Global Broadens Footprint in Asian Market through Collaboration with Law Firm in Sri Lanka18.1.2022 15:30:00 CET | Press release

Andersen Global continues to expand its platform in the Asian market through a Collaboration Agreement with Varners, one of the largest full-service law firms in Sri Lanka. Led by Managing Partner Mahinda Haradasa, Varners specializes in banking and finance, commercial, intellectual property, litigation, real estate and telecommunications, international trade and dispute resolution. Located in Colombo, the firm operates with eight Partners and more than 50 professionals, serving clients at the local and international level. “Our professionals’ extensive industry knowledge and commitment to stewardship has allowed our firm to continually meet the demands of the ever-evolving legal landscape,” Mahinda said. “Our collaboration with Andersen Global is a milestone for us as we look to increase our global reach and meet our clients’ cross-border needs.” “Varners’ commitment to investing in its people and providing clients with best-in-class solutions resonates with our organization’s values

Weber Inc . Transforms Outdoor Cooking With Innovative 2022 Product Portfolio18.1.2022 15:05:00 CET | Press release

Weber Inc. (NYSE:WEBR), the global leader in outdoor cooking innovation, technology, and products, today unveiled the first three new products in its 2022 grilling portfolio. Designed to fuse the best in smart technology, high-quality materials, performance engineering, and craftsmanship, the 2022 GENESIS Smart Gas Grill, 2022 SMOKEFIRE Wood Fired Pellet Grill, STEALTH Edition, and all-new WEBER CRAFTED Outdoor Kitchen Collection take cooking outdoors to new levels of food discovery and exploration. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220118005538/en/ Weber Genesis Smart Gas Grill, Model EPX-335. (Photo: Business Wire) “Our product lineup for the upcoming barbecue season pushes the boundaries of the types of cooking that can be done outdoors, including bringing popular methods like flat top cooking and baking right to a WEBER grill,” said Jennifer Bonuso, Senior Vice President and General Manager, Global Product M

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom